Mark Edward Hatley MD PhD

Pediatric Hematology & Oncology•Memphis, TN

Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology

Associate Member, St. Jude Children's Research Hospital

St. Jude Children's Research Hospital262 Danny Thomas PlaceMemphis, TN 38105

Dr. Hatley is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hatley's full profile Already have an account?

Summary

Dr. Mark Hatley is a pediatric hematologist/oncologist and scientist. Dr. Hatley is the Director of the Molecular Oncology Division at St. Jude Children's Research Hospital in Memphis, TN. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 13 years. He specializes in pediatric sarcoma oncology and is experienced in sarcomas, molecular biology, and sarcoma biology.

Education & Training

University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2006 - 2010
University of Texas Southwestern Medical CenterResidency, Pediatrics, 2004 - 2006
University of Texas Southwestern Medical SchoolClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TN State Medical License 2012 - 2027
TX State Medical License 2009 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Member American Pediatric Society, 2023
Member American Society of Clinical Investigation, 2020
Member Society for Pediatric Research, 2020

Publications & Presentations

PubMed

RNA quality control enables antibiotic tolerance.
Andrew T Nishimoto, Juan C Ortiz-Marquez, Michelle R Scribner, Yanying Yu, Qidong Jia
Cell Host & Microbe. 2026-08-12
Pediatric sarcomas: challenges and opportunities.
Yuan Gao, Kelly M Bailey, Samuel C Blackman, John H Bushweller, Shasha Chong
Genes & Development. 2026-08-04
Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.
Joseph S Baxter, Claudia Montiel Equihua, Jan J Molenaar, Jamie Aye, Gianni Bisogno
British Journal of Cancer. 2026-08-01

Press Mentions

Four Young Pediatric Cancer Research Fellows Earn Nearly $1 Million in AwardsJuly 16th, 2019
From the Cloud to the Clinic, Wide Range of St. Jude Research Presented at AACR 2018April 12th, 2018
Rhabdomyosarcoma Cell Origin Affects Treatment and Survival of Pediatric PatientsFebruary 8th, 2018

Grant Support

Mechanistic dissection and targeting non-cell autonomous tumor promotion in DICER1 cancer predispositionST. JUDE CHILDREN'S RESEARCH HOSPITAL2026–2031
Mediators Of Arrested Differentiation In Pediatric RhabdomyosarcomaST. JUDE CHILDREN'S RESEARCH HOSPITAL2021–2026
Mediators Of Arrested Differentiation In Pediatric RhabdomyosarcomaST. JUDE CHILDREN'S RESEARCH HOSPITAL2021–2026
Mediators of arrested differentiation in pediatric rhabdomyosarcomaNational Cancer Institute (NCI), NIH2021–2026
Defining the non-myogenic origins of pediatric rhabdomyosarcomaNational Cancer Institute (NCI), NIH2017–2023